Baird analyst David Rescott lowered the firm’s price target on Edwards Lifesciences (EW) to $87 from $88 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Completes Key Study on SAPIEN XT THV
- Edwards Lifesciences price target raised to $101 from $96 at Citi
- Edwards Lifesciences price target raised to $103 from $99 at Barclays
- Edwards Lifesciences price target raised to $100 from $95 at RBC Capital
- Edwards Lifesciences price target raised to $92 from $90 at Truist